Sulfa antibiotics work by mimicking PABA (para-aminobenzoic acid), a small molecule bacteria need to build folate. By occupying the active site of the bacterial enzyme dihydropteroate synthase, they block folate synthesis at its first step. Humans do not build folate at all — we absorb it from food, and we have no dihydropteroate synthase — so the target does not exist in us. That is what makes the sulfonamide half of the drug so cleanly selective.

Educational reference — not medical advice. This page describes what is generally known about a drug family. It cannot account for your history, your other medicines, or your circumstances. Decisions about your own treatment belong with your doctor or pharmacist.

The folate pathway, briefly

Bacteria, like all living cells, need folate to make DNA and certain amino acids. Unlike us, most bacteria cannot import folate efficiently from their environment; they synthesise it. The pathway begins with PABA, a small aromatic compound, which is joined to a pteridine fragment by the enzyme dihydropteroate synthase. The product is dihydropteroate, which is converted in two further steps to tetrahydrofolate, the active form.

Sulfa antibiotics resemble PABA closely enough to occupy the same enzyme pocket. The active site accepts the drug; the reaction does not proceed. Folate synthesis stalls. Bacterial growth slows or stops.

The structural reason is on the chemistry page: it is the arylamine on the sulfonamide ring that allows it to mimic PABA. Non-antibiotic sulfonamides — furosemide, HCTZ, celecoxib, the sulfonylureas — lack this group and do not interact with the folate pathway at all.

Why it doesn't poison us

Humans obtain folate from food: leafy greens, legumes, fortified cereals. We have no dihydropteroate synthase to inhibit. The drug therefore acts on the bacterial enzyme without an obvious human counterpart. This is the kind of selective toxicity that makes a useful antibiotic. The same logic underlies the safety of most older antibacterials.

That selectivity has limits. Sulfa drugs have side effects unrelated to the folate pathway — rashes, photosensitivity, marrow effects — and these are the basis of much of the clinical concern with the drug class. The side effects page covers them.

Trimethoprim and the synergy

The most prescribed sulfa drug is not a sulfonamide alone, but a fixed combination: sulfamethoxazole/trimethoprim, sold as Bactrim or Septra. Each component blocks a different step of folate metabolism: sulfamethoxazole blocks dihydropteroate synthase; trimethoprim blocks the next enzyme, dihydrofolate reductase. Together the two drugs cut the pathway twice.

The combination is more than additive, though not for the reason usually given. The textbook explanation is "sequential blockade" — two locks on the same door. Modelling work has shown that a one-way sequential block cannot account for how potent the pairing actually is. The real mechanism runs both ways: tetrahydrofolate is itself needed to manufacture the pterin precursor that dihydropteroate synthase consumes, so trimethoprim, by depleting tetrahydrofolate, also starves the enzyme that sulfamethoxazole is inhibiting. Each drug potentiates the other.

"Bactericidal" also deserves a qualifier. Each drug alone is bacteriostatic; the pair kills, but by a specific route — folate depletion starves the cell of thymidine, and DNA replication collapses in what is called thymineless death. Supply thymidine from outside and the killing stops. This is why pus and necrotic tissue, both thymidine-rich, blunt sulfonamide activity, and why susceptibility testing has to be done on thymidine-poor media. Bactericidal in the urinary tract is not the same claim as bactericidal everywhere.

The two halves are selective in different ways, and only one is absolute. Humans have no dihydropteroate synthase, so sulfamethoxazole has no human target to hit — selectivity by absence. Trimethoprim is a different story: we do have dihydrofolate reductase, and trimethoprim does inhibit it. What saves us is affinity. Trimethoprim binds the bacterial enzyme roughly a hundred thousand times more tightly than the human one. That is a very large margin, but it is a margin rather than an impossibility, which is why folate-related blood changes can appear in elderly patients, in kidney failure, or where folate stores are already low — and why TMP-SMX is contraindicated in megaloblastic anaemia due to folate deficiency. The common one-liner that "humans get folate from food, so the drug is safe for us" is right about the sulfonamide and wrong about the trimethoprim.

Resistance

Bacteria evolve around drug pressure. Resistance to sulfonamides is widespread and well described. Mechanisms include altered dihydropteroate synthase enzymes that bind the drug poorly, increased PABA production, and acquisition of alternative folate synthesis genes on plasmids. Resistance is a major reason sulfa antibiotics are used for narrower indications today than in the 1940s, when they were the first effective antibacterials and the workhorse of treatment for streptococcal infection. The history page traces the arc.

Mechanism vs allergy

Mechanism and allergy are different questions and rest on different parts of the molecule. The drug's mechanism depends on the arylamine that mimics PABA. Most drug allergy to sulfa antibiotics is also linked, indirectly, to the arylamine — through reactive metabolites that bind to host proteins. This is why sulfa allergy is largely a phenomenon of antibiotic sulfonamides and only rarely of non-antibiotic ones. The distinction is the basis of the modern view on cross-reactivity.

Mechanism does not predict tolerance. Two patients with identical bacterial infections may tolerate the same drug very differently. Whether a particular person can take a sulfa antibiotic depends on their allergy history and on the prescriber's clinical judgement, not on the textbook mechanism alone.

Other sulfonamides, other mechanisms

The non-antibiotic sulfonamides each have their own target, unrelated to bacterial folate synthesis. Furosemide inhibits the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle. HCTZ blocks the Na⁺-Cl⁻ cotransporter in the distal tubule. Sulfonylureas close ATP-sensitive potassium channels on pancreatic β-cells. Acetazolamide inhibits carbonic anhydrase. Celecoxib selectively blocks COX-2. The shared sulfonamide group is, in each case, just a piece of the binding site.

How sulfa drugs work.